Zobrazeno 1 - 10
of 697
pro vyhledávání: '"HER2 + breast cancer"'
Autor:
Fei Fei Gong, Eli Grunblatt, Woo Bin Voss, Vibhav Rangarajan, Sasan Raissi, Kimberly Chow, Lua Jafari, Nikita P. Patel, Inga Vaitenas, Milica Marion, Haydee Ramirez, Manyun Zhao, Adin-Christian Andrei, Abigail S. Baldridge, Gillian Murtagh, Kameswari Maganti, Vera H. Rigolin, Nausheen Akhter
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Background Global longitudinal strain (GLS) has been used to identify patients at risk for cancer-therapy related cardiac dysfunction (CTRCD). However, there is limited data on the effectiveness of initiating cardioprotective therapy based o
Externí odkaz:
https://doaj.org/article/298e2c0a98b74aea957fbb0b43e94125
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Background While trastuzumab has been shown to improve disease-free and overall survival in patients with HER2-positive breast cancer, it may also cause trastuzumab-induced cardiotoxicity (TIC). Although racial and ethnic minorities are at h
Externí odkaz:
https://doaj.org/article/096b2f47c44b4dfa86207b9dad971720
Autor:
Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep R. Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, Dae-Won Lee, James M. Reuben, Aysegul Sahin, Lei Huo, Debu Tripathy, Seock-Ah Im, Naoto T. Ueno
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)
Abstract Background Anti-HER2 therapies, including the HER2 antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpressing (HER2+) metast
Externí odkaz:
https://doaj.org/article/96dec9fe852b4c2f9909c30d5560016b
Publikováno v:
South African Journal of Oncology, Vol 8, Iss 0, Pp e1-e10 (2024)
Background: The increasing awareness of chemotherapy-related cardiotoxicity has established a unique sub-speciality – cardio-oncology. However, consensus guidelines are still emerging. Patients at risk of cardiotoxicity should be identified and man
Externí odkaz:
https://doaj.org/article/cd7aed78173144d39c23404c2b81524d
Autor:
Edoardo Mortato, Anna Paola De Caro, Luca Schinzari, Sonia Maniglio, Carmelo Laface, Gerardo Cazzato, Caterina Foti, Francesca Ambrogio
Publikováno v:
Dermatology Reports (2024)
Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negat
Externí odkaz:
https://doaj.org/article/19c212d4e0254df69c24250730100298
Autor:
Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone, Anne Janin, Gilles Paintaud, Guilhem Bousquet
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the lim
Externí odkaz:
https://doaj.org/article/e86f2a9c1410412ea0b96fb01811d5ae
Autor:
Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou, Xiaohua Zeng
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-20 (2024)
Abstract Background This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients. Methods A total of 120 plasma s
Externí odkaz:
https://doaj.org/article/b50116fb243a46849bead7251c0693c1
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionModern cancer treatment strategies aim at achieving cancer remission by using targeted and personalized therapies, as well as harnessing the power of the immune system to recognize and eradicate the cancer cells. To overcome a relatively
Externí odkaz:
https://doaj.org/article/b2f50da64fd541d6904d0327ff9ef598
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Purpose This research designeded to: 1. Analyze the efficacy and safety of Palbociclib treatment in HR-positive and HER2-negative (HR + /HER2-) metastatic breast cancer(MBC) patients. 2. Establish and validate a nomogram model for predicting
Externí odkaz:
https://doaj.org/article/d575d5c73f3f4d8f86c236af2827c9c8
Autor:
Kerigo Ndirangu, Rachel Goldgrub, Vanita Tongbram, Rajee Anton, Bagrat Lalayan, Joyce O’Shaughnessy, Sarah E Schellhorn
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 6 (2024)
Aim: This systematic literature review aims to summarize the efficacy/effectiveness of treatments, including eribulin (ERI)-based and anti-human epidermal growth factor receptor 2 (HER2) treatments in advanced/metastatic HER2+ breast cancer. Method
Externí odkaz:
https://doaj.org/article/ec6775bd5d1b4893a90d684dd77a5e46